Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | CTSA | P10619 | 4/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217201 | 0.94 | FFAR1 (0.39) | ADORA2BADORA1ADORA2ACTSAFFAR1 | |
| SCHEMBL30217199 | 0.89 | CDK8 (0.33) | DNMT3BBACE1BACE2 | |
| SCHEMBL30217105 | 0.89 | CYP4F2 (0.34) | — | |
| SCHEMBL30217154 | 0.88 | CNR2 (0.33) | DNMT3BBACE1BACE2 | |
| SCHEMBL30217364 | 0.81 | CDK8 (0.32) | DNMT3BBACE1BACE2 | |
| SCHEMBL30217228 | 0.81 | CYP4F2 (0.42) | — | |
| SCHEMBL30217117 | 0.79 | CDK8 (0.32) | DNMT3BBACE1BACE2 | |
| SCHEMBL30217178 | 0.79 | BRD4 (0.33) | DNMT3BBACE1BACE2 | |
| SCHEMBL30217248 | 0.79 | FFAR1 (0.31) | FFAR1 | |
| SCHEMBL30217314 | 0.78 | BACE1 (0.32) | DNMT3BBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034992-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |